Chronic Hepatitis C Virus Infection, a New Cardiovascular Risk Factor?

Fanny Domont; Patrice Cacoub


Liver International. 2016;36(5):621-627. 

In This Article

Cardiovascular Disease-related Mortality in HCV-infected Patients

A retrospective cohort study from United States showed an increased cardiovascular mortality among more than 10 200 HCV-seropositive blood donors compared to more than 10 200 HCV seronegative subjects (HR 2.21; 95% CI: 1.41–3.46).[15] A prospective Japanese study of 1077 adult haemodialysis patients without hepatitis B virus infection included 968 HCV seronegative, 55 HCV-seropositive HCV RNA negative and 79 HCV RNA positive patients.[46] The sex- and age-adjusted mortality rate was 71.9, 80.4 and 156 respectively. The RRs (95% CI) for death in HCV RNA negative vs HCV RNA positive patients were 1.23 (0.72–2.12) vs 1.60 (1.13–2.28) for all-cause death and 0.75 (0.28–2.02) vs 1.64 (0.98–2.73) for cardiovascular death. A recent meta-analysis on 22 studies that compared the occurrence of cardiovascular diseases between HCV-infected and HCV-uninfected subjects found that HCV-infected patients had increased risks of cardiovascular diseases-related mortality (OR 1.65; 95% CI: 1.07–2.56; P = 0.02), even greater in patients with diabetes and hypertension.[47] A meta-analysis in haemodialysis patients found that anti-HCV antibody positivity is an independent and significant risk factor for death, with an adjusted RR for cardiovascular mortality of 1.26 (95% CI: 1.10–1.45).[48]